We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+31.06%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.34B
AUM Growth
+$386M
Cap. Flow
+$185M
Cap. Flow %
13.81%
Top 10 Hldgs %
66.32%
Holding
61
New
9
Increased
9
Reduced
28
Closed
9

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$48.6M
2
SAGE
Sage Therapeutics
SAGE
+$40.7M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$24.8M
4
TSRO
TESARO, Inc.
TSRO
+$22.5M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$19.1M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$25.1M
2
KA
Kineta, Inc. Common Stock
KA
+$19.2M
3
ANAB icon
AnaptysBio
ANAB
+$16.6M
4
BLUE
bluebird bio
BLUE
+$14.2M
5
WVE icon
Wave Life Sciences
WVE
+$7.09M

Sector Composition

Rank Sector Weight
1 Healthcare 83.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
26
DELISTED
Array Biopharma Inc
ARRY
$10.9M 0.81%
668,743
-31,257
-4% -$501K
OMER icon
27
CALL
Omeros
OMER
$931M
$10.8M 0.81%
969,000
-781,000
-45% -$11M
BOLD
28
DELISTED
Audentes Therapeutics, Inc
BOLD
$9.7M 0.72%
322,945
-14,931
-4% -$505K
RETA
29
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$9.23M 0.69%
450,000
+250,000
+125% +$6.43M
ACRS icon
30
Aclaris Therapeutics
ACRS
$831M
$9.21M 0.69%
525,538
-24,462
-4% -$518K
ABEO icon
31
Abeona Therapeutics
ABEO
$389M
$7.88M 0.59%
21,976
-1,024
-4% -$380K
BHVN
32
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$7.33M 0.55%
284,735
-13,068
-4% -$391K
COLL icon
33
Collegium Pharmaceutical
COLL
$1.15B
$7.32M 0.55%
286,668
-13,332
-4% -$318K
SGMO
34
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$7.26M 0.54%
382,192
-17,808
-4% -$381K
ZLAB icon
35
Zai Lab
ZLAB
$2.08B
$7.11M 0.53%
333,166
– –
KDMN
36
DELISTED
Kadmon Holdings, Inc.
KDMN
$7.01M 0.52%
+1,648,432
New +$7.05M
MTVA
37
MetaVia Inc
MTVA
$7.69M
$6.78M 0.51%
16
+4
+33% +$2.03M
CFRX
38
DELISTED
ContraFect Corporation
CFRX
$5.39M 0.4%
4,240
-198
-4% -$244K
HRTX icon
39
Heron Therapeutics
HRTX
$98.4M
$5.28M 0.39%
191,108
-8,892
-4% -$202K
SLDB icon
40
Solid Biosciences
SLDB
$851M
$5.14M 0.38%
+45,731
New +$15.4M
ARNA
41
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.94M 0.37%
+125,000
New +$4.86M
INDP icon
42
Indaptus Therapeutics
INDP
$183M
$4.89M 0.36%
345
-17
-5% -$241K
TRIL
43
DELISTED
Trillium Therapeutics Inc.
TRIL
$4.13M 0.31%
573,208
-26,792
-4% -$203K
NERV icon
44
Minerva Neurosciences
NERV
$191M
$3.8M 0.28%
75,988
– –
PTGX icon
45
Protagonist Therapeutics
PTGX
$8.85B
$3.28M 0.24%
382,139
-17,861
-4% -$336K
EOLS icon
46
Evolus
EOLS
$400M
$3.09M 0.23%
+342,400
New +$3.92M
XLRN
47
DELISTED
Acceleron Pharma
XLRN
$2.8M 0.21%
71,667
-3,333
-4% -$142K
JNCE
48
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.85M 0.14%
82,988
-284,235
-77% -$6.31M
MRNS
49
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.83M 0.14%
119,528
-5,472
-4% -$130K
ONSIZ
50
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$18K ﹤0.01%
416,666
– –
1
2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2018 Portfolio in Review

As of Q1 2018, Cormorant Asset Management held 61 positions worth $1.34B, up 40% from $955M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Cormorant Asset Management deployed $185M of net new capital in Q1 2018, opening 9 new positions and adding to 9 existing holdings. Its largest new stake was Sage Therapeutics: 239,619 shares worth $38.6M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 83% a quarter earlier.

On the sell side, the largest reduction was AnaptysBio, an estimated $16.6M trimmed.

  • Cormorant Asset Management's largest Q1 2018 buy was Sage Therapeutics: 239,619 shares worth $38.6M.
  • Cormorant Asset Management added most to Nektar Therapeutics in Q1 2018, an estimated $48.6M increase.
  • Cormorant Asset Management's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $16.6M.
  • Cormorant Asset Management fully exited Juno Therapeutics, Inc. in Q1 2018, selling an estimated $25.1M.
  • Cormorant Asset Management's ten largest holdings make up 66% of its $1.34B portfolio in Q1 2018.
  • Cormorant Asset Management opened 9 new positions and closed 9 in Q1 2018.
  • Cormorant Asset Management's portfolio value rose 40% quarter-over-quarter to $1.34B.

Based on Cormorant Asset Management's 13F filing for Q1 2018, filed 15 May 2018.